Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: October 15, 2007
Last updated: July 25, 2014
Last verified: July 2014

This study aims to provide a holistic assessment of patients receiving etanercept in a real-world setting.

Condition Intervention
Ankylosing Spondylitis
Drug: Etanercept

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A 1 Year Observational Study Of The Use Of Etanercept In Routine German Clinical Practice To Treat Ankylosing Spondylitis (AS) Patients: An Effectiveness, Safety And Health Economic Evaluation

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Proportion of patients achieving remission determined by ASAS criteria for partial remission [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determination of adverse events (AE) and serious adverse events (SAE) rates on etanercept therapy [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Determination of differents in AE rates between patients with specific co-morbidities, such as cardiovascular disease and metabolic disorders [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Assessment of patient outcome [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Assessment of work disability domains [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 1715
Study Start Date: November 2007
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients with Ankylosing Spondylitis Drug: Etanercept
The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Other Name: Enbrel

Detailed Description:

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with an established diagnosis of Ankylosing Spondylitis


Inclusion Criteria:

  • Diagnosis of ankylosing spondylitis (AS)

Exclusion Criteria:

  • Hypersensitivity to etanercept
  • Active infection including chronic or localised infection
  • Sepsis or risk of sepsis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00544557

Pfizer Investigational Site
Berlin, Germany, 12200
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT00544557     History of Changes
Other Study ID Numbers: 0881X1-4463, B1801087
Study First Received: October 15, 2007
Last Updated: July 25, 2014
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Spondylitis, Ankylosing
Bone Diseases
Bone Diseases, Infectious
Joint Diseases
Musculoskeletal Diseases
Spinal Diseases
TNFR-Fc fusion protein
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Gastrointestinal Agents
Immunologic Factors
Immunosuppressive Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on May 03, 2015